# DEWI: HCP commentary report

> 18 verified statements (10 from clinicians verified by NPI or staff page) from 10 commentary sources · 4 findings · updated Oct 29, 2026

## Report

- Trial: Watch-and-wait Strategy to Initiate Dostarlimab-based Immunotherapy in Localized Deficient Mismatch Repair (dMMR) and/or Microsatellite Instability High (MSI-H) oEso-gastric Junction and Gastric Adenocarcinoma: An Open-label GERCOR Phase II Study
- NCT ID: NCT06059495
- Registry: https://clinicaltrials.gov/study/NCT06059495
- Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
- Phase: Phase 2
- Status: Recruiting
- Drugs tested: dostarlimab
- Indication: localized dMMR/MSI-H gastric/GEJ adenocarcinoma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-29
- Last checked: 2026-10-29
- Release hash: 509caccbe1d2ad613bc4783cce6c5872fc873d416de674d92c3054b6e0a4e790

## Counts

- HCP commentary sources screened: 32
- Sources cited by verified statements: 10
- Verified statements: 18
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 10
- Findings: 4
- Named people in screened sources (unnamed speakers and accounts not counted): 10
- Voices cited: 9
- Cited voices identity-verified: 9
- Organisational or shared accounts (not counted as people): 2

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

DEWI asks whether dostarlimab can support watch-and-wait instead of surgery in localized dMMR/MSI-H gastric or gastroesophageal junction adenocarcinoma. One X poster welcomes the possibility of organ preservation but treats surgery omission as conditional rather than automatic. That poster questions confidence in complete response and its durability, leaving safe patient selection unresolved. The sources reviewed for this edition place DEWI’s phase II first-interim results at ESMO 2026.

## Open Medical Affairs question

What response-validation, durability and safety evidence would justify selective surgery avoidance, including in patients at high surgical risk?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. A possible high-surgical-risk exception is not a general practice change
- F2. Confidence in complete response and its durability remains a condition of surgery avoidance
- F3. Strong enthusiasm for upper-GI organ preservation coexists with a qualified rectal-cancer analogy
- F4. Patients without cCR prompt an unanswered radiotherapy question and interest in alternative checkpoint regimens

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 4 | 2 | 2 | 2 | none recorded | 2 |
| F2 | 5 | 5 | 5 | 4 | none recorded | 2 |
| F3 | 7 | 6 | 6 | 6 | recorded | 2 |
| F4 | 3 | 2 | 1 | 2 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 2 | 1 | 0 | 0 | 1 | 4 | 0 | 2 posts and articles | yes |
| F2 | 2 | 3 | 0 | 0 | 0 | 5 | 0 | 5 posts and articles | yes |
| F3 | 4 | 1 | 0 | 1 | 1 | 7 | 0 | 6 posts and articles | yes |
| F4 | 1 | 1 | 0 | 1 | 0 | 3 | 0 | 1 post or article | yes |

### Trial dimensions

- Primary endpoint: Clinical complete response (cCR): F1 (1 shared claims), F2 (4 shared claims), F3 (4 shared claims), F4 (1 shared claims)
- Secondary endpoints: F1 (1 shared claims), F2 (2 shared claims), F3 (2 shared claims), F4 (1 shared claims)
- Population and setting: F1 (3 shared claims), F2 (1 shared claims), F3 (3 shared claims), F4 (1 shared claims)
- The comparison: F1 (3 shared claims), F2 (1 shared claims), F3 (2 shared claims), F4 (3 shared claims)
- Safety and tolerability: F1 (1 shared claims)
- Design and conduct: F2 (2 shared claims), F3 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. A possible high-surgical-risk exception is not a general practice change

An X post asks whether surgery should remain the default following a complete response to immunotherapy in DEWI.

Source: X thread, 2026-10-23.

### F2. Confidence in complete response and its durability remains a condition of surgery avoidance

X posts ask about verifying a complete response and whether surgery can be avoided with dostarlimab in DEWI.

Source: X thread, 2026-10-23.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 18 | Paid |
| Trial aspects mapped | 10 | Free |
| Sources with links | 10 | Counts free |
| Speaker attribution for cited voices | 9 | Paid |

## Trial aspects

10 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Clinical complete response (cCR) | discussed | 9 | 8 |
| Secondary endpoints | discussed | 5 | 5 |
| Population and setting | discussed | 7 | 5 |
| The comparison | discussed | 8 | 5 |
| Safety and tolerability | discussed | 1 | 1 |
| Design and conduct | discussed | 3 | 3 |
| Practice change and possible high-surgical-risk exceptions | discussed | 3 | 2 |
| Response verification, residual risk and safe selection | discussed | 3 | 2 |
| Options for patients without cCR | discussed | 2 | 1 |
| Rectal-cancer precedent and other organ-preservation approaches | discussed | 4 | 4 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 26 | 10 |
| Bluesky threads | 4 | 0 |
| LinkedIn posts | 1 | 0 |
| Podcasts | 1 | 0 |

- Screened window: 2025-01-15 to 2026-10-26
- Cited window: 2026-10-20 to 2026-10-25
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Watch-and-wait Strategy to Initiate Dostarlimab-based Immunotherapy in Localized Deficient Mismatch Repair (dMMR) and/or Microsatellite Instability High (MSI-H) oEso-gastric Junction and Gastric Adenocarcinoma: An Open-label GERCOR Phase II Study
- Registry: NCT06059495 (https://clinicaltrials.gov/study/NCT06059495)
- Study IDs: DEWI G-123 · 2023-506102-39-00 (EU CT)
- Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
- Design: Phase 2 · interventional, na, single group, phase2
- Status: Recruiting
- Enrollment: 89 (estimated)
- Start: 2024-01-22 (actual)
- Primary completion: 2028-09-01 (estimated)
- Primary endpoint: Clinical complete response (cCR) (At 1 year from the start of treatment with dostarlimab.)
- Intervention: Dostarlimab (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 1 matching source (1 X thread) could not be read and is not included.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 17 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- This is not a complete survey of public discussion or clinician opinion. Some potentially relevant passages were not fully assessed, one discussion was unavailable, and unnamed references or alternative spellings may be missing.
- No trial-specific results publication or protocol was available for direct comparison. A dostarlimab regulatory label was also unavailable; these sources do not establish approved use.
- The cited 24-patient first-interim analysis and 43-patient summary have different denominators and follow-up. Their juxtaposition does not establish a change in efficacy over time.
- Reports of no relapse or death concern the specified complete responders at the stated follow-up. They should not be generalized to all treated patients or interpreted as cure.
- Repeated abstract information, reposts, institutional wording and a linked article summary are not additional independent HCP opinions.
- One author is unnamed; that author's clinical role is not established in the sources reviewed for this edition. Credentials described by sources for some other authors are not independently confirmed clinical roles.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-29: current edition, corrected 2026-10-29
  - Correction 2026-10-29: Corrected to match the delivered report: the sample findings. The page names the trial's tested drugs (dostarlimab) and indication (localized dMMR/MSI-H gastric/GEJ adenocarcinoma).

Last checked for new commentary 2026-10-29. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (18 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (9 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/dewi-nct06059495
- Agents: POST https://www.erudio.com/api/orders with {"report": "dewi-nct06059495", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=dewi-06059495

## Cite

Erudio Health. DEWI (NCT06059495): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/dewi-nct06059495

## Machine access

- JSON: https://www.erudio.com/reports/dewi-nct06059495.json
- Markdown: https://www.erudio.com/reports/dewi-nct06059495.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "dewi-06059495"}`